Budesonide

證據等級: L5

預測適應症: 10 個

Budesonide: From Inflammatory Conditions to Atopic Eczema

One-Sentence Summary

Budesonide is a potent synthetic glucocorticoid used globally for asthma, COPD, allergic rhinitis, and inflammatory bowel conditions; however, no approved indication is currently recorded in the Italian AIFA database. The TxGNN model predicts it may be effective for Atopic Eczema, based on its mechanism of suppressing Th2 cytokines that are central to this skin disease. Current evidence consists of 2 retrieved clinical trials (neither directly evaluating budesonide for eczema) and 20 publications — with the strongest direct support being a 2024 preclinical nanoparticle formulation study — placing the overall evidence level at L4.

Quick Overview

Item	Content
Original Indication	No approved indication found in Italian AIFA database
Predicted New Indication	Atopic Eczema
TxGNN Prediction Score	99.96%
Evidence Level	L4
Italy Market Status	Not Marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Budesonide is a potent synthetic glucocorticoid that exerts its anti-inflammatory effects by binding to intracellular glucocorticoid receptors (GR). Once bound, it suppresses the transcription of key Th2 cytokines — including IL-4, IL-5, and IL-13 — while simultaneously inhibiting eosinophil recruitment and reducing NF-κB-driven inflammatory cascades. Detailed MOA data from DrugBank was not available for this evaluation; the mechanism described here is based on established pharmacological knowledge and the repurposing rationale provided in the evidence pack.

Atopic eczema (ICD-10 L20) is primarily driven by a Th2-dominant inflammatory response, characterized by elevated IL-4/IL-13 signaling, impaired skin barrier function, and eosinophilic tissue infiltration. Budesonide's mechanism of directly suppressing these same cytokine pathways provides a mechanistically coherent rationale for its potential utility in this indication. In fact, topical corticosteroids broadly are already a first-line treatment for atopic dermatitis — the question for this repurposing candidate lies in whether budesonide specifically, particularly in novel delivery formats, offers meaningful advantages.

One additional note of caution: TxGNN ranked both "atopic eczema" (rank #1, score 99.96%) and "dermatitis, atopic" (rank #3, score 99.81%) as separate predictions. These are clinically the same entity (ICD-10 L20), suggesting the model is predicting the same indication from two different knowledge graph nodes. The most direct human evidence in the literature comes from PMID 38275852 (2024), which developed pH-sensitive budesonide nanoparticle hydrogels explicitly designed for pediatric atopic dermatitis, confirming the recognized pharmacological rationale. However, this remains a preclinical formulation study.

Clinical Trial Evidence

Neither of the two retrieved trials directly evaluates budesonide as a treatment for atopic eczema. Both are Grade C — atopic disease appears as a background enrollment criterion or co-morbidity, not as the primary treatment target.

Trial Number	Phase	Status	Enrollment	Key Findings
NCT04680117	NA	Unknown	150	Characterizes severe pediatric asthma endotypes using immune, metabolomics, and microbial analyses; atopy (including eczema) is a background phenotypic variable, not a treatment endpoint — not applicable as budesonide-for-eczema evidence
NCT01028560	Phase 1/2	Completed	58	Allergy immunotherapy (not budesonide) in atopic wheezing children at high risk for asthma; eczema is listed as an enrollment risk factor — not applicable as direct treatment evidence

Literature Evidence

PMID	Year	Type	Journal	Key Findings
38275852	2024	Preclinical / Formulation	Gels (Basel)	Budesonide-loaded Eudragit L100 nanoparticles formulated into pH-sensitive hydrogels for local therapy of pediatric atopic dermatitis; exploits pH changes in atopic lesions for targeted release — strongest direct evidence available, but preclinical only
21062310	2010	Veterinary RCT	J Vet Pharmacol Ther	Randomized, blinded, placebo-controlled crossover trial (n=29 dogs) of 0.025% budesonide leave-on conditioner (Barazone) for canine atopic dermatitis; significantly reduced skin lesions and pruritus — only controlled trial evidence, but in a non-human model
9496795	1998	Clinical Study	Pediatric Dermatology	Knemometry study in 14 children (5–12y) with atopic dermatitis treated with topical budesonide; detected measurable systemic glucocorticoid activity — confirms dermal absorption and systemic safety concern in children
8864369	1996	Clinical Study	Dermatology (Basel)	Topical glucocorticosteroids in children with atopic dermatitis assessed for effects on IGF axis, bone collagen turnover; percutaneous absorption confirmed — relevant safety baseline for pediatric topical use
19875223	2010	Prospective Clinical	Allergologia et Immunopathologia	Differential budesonide response in atopic vs. non-atopic infants with recurrent wheezing; atopic status modulated therapeutic response — indirect evidence of pharmacological sensitivity in the atopic phenotype
33931866	2021	Cross-sectional	Contact Dermatitis	Italian SIDAPA baseline patch-test series (2018–2019): budesonide allergy frequency has declined over two decades; confirms budesonide remains the standard corticosteroid hypersensitivity marker in Italy
35133669	2022	Cross-sectional	Contact Dermatitis	Contact sensitization patterns in Asian dermatology patients with and without atopic dermatitis; similar or higher patch-test positivity in AD patients — relevant safety signal for topical budesonide use
31705907	2020	Review	J Allergy Clin Immunol	Review of emerging EoE therapies; swallowed topical corticosteroids (including budesonide) are current standard off-label treatment — demonstrates established mucosal anti-inflammatory role with shared Th2 mechanistic basis
14616123	2003	Review	Allergy	Corticosteroid hypersensitivity in asthma patients; budesonide identified as causing delayed contact allergy — safety signal directly relevant to topical application in atopic patients
19571596	2009	Review	Neuroimmunomodulation	Intranasal corticosteroids and HPA axis suppression; discusses systemic safety in patients with comorbid allergic rhinitis and atopic dermatitis — supports need for systemic monitoring in polytherapy contexts

Italy Market Information

Budesonide is not registered in the Italian AIFA database. No authorized product records are available for this market.

Safety Considerations

Please refer to the package insert for safety information.

⚠️ Important Safety Signal Identified in the Literature: Multiple independent studies — including PMID 30053491, 24603519, 35184304, 19183418, and 37550231 — consistently report that budesonide is a recognized contact allergen in patients with atopic dermatitis, falling within the Group B corticosteroid cross-reactivity cluster. This creates a therapeutic paradox: the intended anti-inflammatory agent may itself act as a sensitizing hapten in the target patient population. This finding is specific to topical administration routes and must be addressed as a priority safety concern before any clinical investigation in atopic eczema proceeds.

Conclusion and Next Steps

Decision: Hold

Rationale: The mechanistic basis for budesonide in atopic eczema is pharmacologically coherent (GR-mediated Th2 suppression), but current evidence is limited to preclinical formulation work and indirect clinical signals. Critically, a well-documented contact sensitization risk in the exact target population creates a safety concern that must be resolved before advancing this candidate.

To proceed, the following is needed:

Safety data gap resolution: Obtain Italian AIFA package insert (Data Gap DG001 — Blocking) and DrugBank MOA data (Data Gap DG002 — High) before any further evaluation stages
Contact sensitization risk assessment: Conduct formal patch-test screening protocol for budesonide hypersensitivity in prospective atopic dermatitis patients; consider Group B corticosteroid cross-reactivity profiling
Human clinical trial evidence: No RCT or prospective human study directly evaluating budesonide for atopic eczema currently exists — a Phase 2 proof-of-concept trial is required to advance to L2 evidence
Novel delivery strategy: If pursuing this indication, prioritize nanoparticle or encapsulated delivery systems (as explored in PMID 38275852) to reduce direct sensitizer exposure and improve local drug concentration
Knowledge graph deduplication: "Atopic eczema" (rank #1) and "Dermatitis, atopic" (rank #3) are the same clinical entity (ICD-10 L20); these two TxGNN predictions should be merged in the pipeline to avoid double-counting evidence and recommendations
Evaluate rank #2 (Bronchitis) as higher-priority candidate: The bronchitis indication carries L2 evidence with a meta-analysis and systematic review directly involving budesonide, and a "Proceed with Guardrails" recommendation — this may represent a more immediate repurposing opportunity
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.